Anderson-Fabry disease is a genetic lysosomal storage disease, linked to chromosome X (gene GLA), responsible of enzyme synthesis deficit in α-galactosidase A with intracellular sphingolipids accumulation and multiorganic achievement.
If renal complication is principally responsible of the pejorative evolution of the disease, it may also exist a cardiac achievement, symptomatic or not (heart failure symptoms including dyspnea, conduction abnormalities, supra-ventricular and ventricular arrhythmias), with or without left ventricular hypertrophy (LVH).
Administration of agalsidase-α or ß, a genetic engineering synthetic equivalent of the deficient enzyme, should significantly slow disease evolution indeed reduce LVH.
Some patients with Fabry disease without LVH should present, compared to healthy subjects, indirect early markers of intramyocyte lipid overload:
Inclusion Criteria:
Patients group :
Healthy volunteers group:
Exclusion Criteria:
For the 2 groups :
For the patients:
- Previous history of hypersensitivity to gadolinium.
patricia.reant@chu-bordeaux.fr(0)5 57 65 64 85 ext. +33
celine.carpentier@chu-bordeaux.fr(0)5 57 65 61 68 ext. +33
Pessac, 33604, France
patricia.reant@chu-bordeaux.fr(0)5 57 65 64 85 ext. +33
celine.carpentier@chu-bordeaux.fr(0)5 57 65 61 68 ext. +33